Merck to Present HIV Treatment Data at 20th European AIDS Conference in Paris

Author: Benzinga Newsdesk | October 09, 2025 07:12am

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025) taking place Oct.15-18, 2025, in Paris, France. The company's presentations will include:

• An oral presentation of weight and body composition at Week 48 from the Phase 3 trial (MK-8591A-052) comparing doravirine/islatravir [DOR/ISL (100mg/0.25mg)] vs. bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50mg/200mg/25mg)] for the once-daily treatment of adults with virologically suppressed HIV-1 infection on antiretroviral therapy
• A poster presentation of fasting lipids and insulin resistance at Week 48 from two Phase 3 trials comparing DOR/ISL vs. baseline antiretroviral therapy (MK-8591A-051) or BIC/FTC/TAF (MK-8591A-052), for the once-daily treatment of adults with virologically suppressed HIV-1 infection on antiretroviral therapy
• An oral presentation of 96 weeks of safety and pharmacokinetics data from the Phase 2 trial (NCT05052996) of the investigational once-weekly oral combination of islatravir in combination with lenacapavir (MK-8591D) for adults with virologically suppressed HIV-1 infection on BIC/FTC/TAF
• A poster presentation of MK-8527 Phase 1 safety and pharmacokinetics data in adults with moderate or severe renal impairment (MK-8527-008); MK-8527 is Merck's investigational once-monthly pill for HIV pre-exposure prophylaxis (PrEP)

Posted In: MRK